Patents by Inventor Galina ZATS

Galina ZATS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF
    Publication number: 20240148653
    Abstract: The present invention provides parenteral pharmaceutical compositions including therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 9, 2024
    Applicant: Mapi Pharma Ltd.
    Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • Semaglutide depot systems and use thereof
    Patent number: 11865213
    Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: January 9, 2024
    Assignee: MAPI PHARMA LTD.
    Inventors: Galina Zats, Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
  • LOW BURST-RELEASE LIRAGLUTIDE DEPOT SYSTEMS
    Publication number: 20230256058
    Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of liraglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release in the first twenty-four hours post administration. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus and Parkinson's disease.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 17, 2023
    Applicant: MAPI PHARMA LTD.
    Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF
    Publication number: 20230014750
    Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 19, 2023
    Applicant: Mapi Pharma Ltd.
    Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
  • Intermediate compounds and process for the preparation of efinaconazole
    Patent number: 9617241
    Abstract: The present invention relates to a process for the preparation of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (Efinaconazole) and intermediates used in such process.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: April 11, 2017
    Assignee: MAPI PHARMA LTD.
    Inventors: Anna Gopin, Shai Rubnov, Galina Zats, Ehud Marom
  • INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF EFINACONAZOLE
    Publication number: 20160355500
    Abstract: The present invention relates to a process for the preparation of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (Efinaconazole) and intermediates used in such process.
    Type: Application
    Filed: March 2, 2015
    Publication date: December 8, 2016
    Applicant: MAPI PHARMA LTD.
    Inventors: Anna GOPIN, Shai RUBNOV, Galina ZATS, Ehud MAROM